作为一名物理学家,他很深,刻薄且高度数学。他在严格理论中的工作保持着与现实的接触,建立了公理场理论的抽象与基本粒子碰撞的描述之间的桥梁。在几篇基本论文中,他建立了在质子蛋白和proton-proton和pro ton-antiproton碰撞中使用分散关系所需的分析性能,这是使用Asymp Totic定理的出发点,以最大程度地生长粒子 - 粒子和particle和particle-particle和par- ticle-ticle-tile-ticle-antiparticle碰撞。他将这些结果倾向于生产反应。最近在ISR中使用抗质子和SPS提供了这些结果的壮观实验证明。其他工作为扰动重新归一化理论做出了重要贡献。
世界卫生组织在2020年3月11日宣布全球大流行,2019年冠状病毒疾病2019年冠状病毒疾病。自2019年12月在中国武汉出现以来,它具有许多Devas经济以及社会,心理和物理健康的影响。尽管截至2023年5月,它不再处于全球紧急状态,但自PAN DEMIC开始以来,全球已有760,000,000多人的案件,近700万例。1,2本简短的文献综述旨在研究长期养育和自杀风险之间的联系,并充当提供者治疗长期养育患者的有用资源。该病毒的患者临床表现不同,从完全不良的患者到导致死亡的严重并发症的患者。严重的症状包括肺炎,肺部衰竭,肝脏和肾脏损伤,急性心力衰竭,脑病等;虽然更常见,但温和的症状包括发烧,身体酸痛,咳嗽,呼吸困难和疲劳。3除了19 covid-19的急性病例外,一些患者的症状持续数周,几个月甚至几年后。已经使用几种不同的术语来识别这些长期的symp toms,例如长长的,长霍尔的covid,covid-19条件,慢性卷和急性后的SARS-COV-2(PASC)急性后遗症。4长舒联症状也可能出现,即使患者是不可分割的开始,长期旋转的症状也可能与COVID-19的初始诊断时的症状也有所不同。4个杂化后症状各不相同,通常包括疲劳,头痛,DYS PNEA,胸痛,焦虑和抑郁。3在这篇简短的文献综述中值得注意的是与长期旋转有关的PSY循环症状。认知功能受损,睡眠异常,抑郁,焦虑,创伤后压力
Messenger RNA(mRNA)BNT162B2(辉瑞-biontech)和mRNA-1273(ModernA)Covid-19疫苗已显示可有效防止在随机安慰剂对照的III期试验中预防症状性covid-19(1,2);但是,这些疫苗的益处对预防Asymp Tomatic和症状性SARS-COV-2(导致COVID-19的病毒)感染的好处,尤其是在现实世界中施用的情况下,对这些感染的良好了解不太了解。在2020年12月14日至2021年3月13日,在美国八个地点使用Prospec Tive Cohorts,急救人员以及其他必要和前线工人*,CDC通常每周对SARS-COV-2感染进行了测试,无论症状状态以及与症状状态以及与共同疾病一致的症状发作,无论症状状态如何。在3,950名参与者中,没有先前没有SARS-COV-2感染的实验室文件,2,479(62.8%)接受了建议的mRNA剂量,而477(12.1%)仅接受了一剂MRNA Vac Cine。†在未接种疫苗的参与者中,每1000人日的逆转录 - 聚合酶链反应(RT-PCR)确认1.38 SARS-COV-2感染。相比之下,在完全免疫的人(第二剂量后14天)中,报告了0.04个每1000人的感染,在部分免疫中(初次剂量和
5Q-5D-5L EuroQol-5 Dimensions-5 Levels ACE Adverse childhood experiences AE Adverse event AHRQ Agency for Healthcare Research and Quality Asymp Asymptomatic AUD Alcohol use disorder AUDIT Alcohol Use Disorders Identification Test BDI Beck Depression Inventory BDI-II Beck Depression Inventory II BP Blood pressure CAPS Clinician-Administered PTSD Scale CAPS-4 DSM-4 CAPS-5 CAPS-5临床医生管理的PTSD量表DSM-5 CBTCOGNIɵVE-BEHAVIORAL疗法CE成本效益CI置信区置信度cpt CPT认知处理治疗CRP C-CRP CRP CRP PROTICE cORIBS cOLIMBIBIAD cORIMBIAD SUICICIAD SUICICIAD SUICICIAD SUICICIA SUICICIAD SUICICIAD SUICICIA SUICICIAD SUICICIAD SUICICIAD SUICICIAD SUICIDIA Disorders Identification Test EMDR Eye Movement DesensiƟzaƟon and Reprocessing evLY Equal value life year FDA U.S. Food and Drug Administration HIDI Health Improvement Distribution Index I Insufficient ID Identification ITT Intention to treat LTFUQ Long-term follow-up questionnaire LSNAP Lykos-specific non-assisted psychotherapy M Markov MD Mean difference MDD Major depressive disorder MDMA 3,4-甲基二甲基甲基苯丙胺MDMA-AP MDMA辅助心理疗法mg毫克毫克毫克毫克毫克中等n数字N NA或N/不适用NCT NACT国家临床试验NH非涉及NH未报告的NH未报告的NH未报告的OUD OUD OUD OUD OUD OUD OUD OUD PC PC PC PC Controlly PC PC Conterbo Controlly PCTGI PCTGI PTGI PTGI PTGI PTGI PTGI PTGI PTGI PTGI PTGI PTGI PTGI PTGI PTGI PTGI PTGI质量质量质量质量生活质量RR相对风险
5Q-5D-5L EuroQol-5 Dimensions-5 Levels ACE Adverse childhood experiences AE Adverse event AHRQ Agency for Healthcare Research and Quality Asymp Asymptomatic AUD Alcohol use disorder AUDIT Alcohol Use Disorders Identification Test BDI Beck Depression Inventory BDI-II Beck Depression Inventory II BP Blood pressure CAPS Clinician-Administered PTSD Scale CAPS-4 Clinician-Administered PTSD Scale for DSM-4 CAPS-5 Clinician-Administered PTSD Scale for DSM-5 CBT Cognitive-behavioral therapy CE Cost-effectiveness CI Confidence interval CPT Cognitive processing therapy CRP C-reactive protein CSSRS Columbia Suicide Severity Rating Scale DEA US Drug Enforcement Agency DUDIT Drug Use Disorders Identification Test EMDR Eye Movement Desensitization and Reprocessing evLY Equal value life year FDA U.S. Food and Drug Administration HIDI Health Improvement Distribution Index I Insufficient ID Identification ITT Intention to treat LTFUQ Long-term follow-up questionnaire LSNAP Lykos-specific non-assisted psychotherapy M Markov MD Mean difference MDD Major depressive disorder MDMA 3,4-methylenedioxymethamphetamine MDMA-AP MDMA-assisted psychotherapy Mg Milligram Mod Moderate n Number N Total Number NA or N/A Not applicable NCT National Clinical Trial NH Non-Hispanic NR Not reported OUD Opioid use disorder PC Placebo-controlled PTGI Posttraumatic Growth Inventory PTSD Post-traumatic stress disorder QALY Quality adjusted life year QoL Quality of life RR Relative risk
5Q-5D-5L EuroQol-5 Dimensions-5 Levels ACE Adverse childhood experiences AE Adverse event AHRQ Agency for Healthcare Research and Quality Asymp Asymptomatic AUD Alcohol use disorder AUDIT Alcohol Use Disorders Identification Test BDI Beck Depression Inventory BDI-II Beck Depression Inventory II BP Blood pressure CAPS Clinician-Administered PTSD Scale CAPS-4 Clinician-Administered PTSD Scale for DSM-4 CAPS-5 Clinician-Administered PTSD Scale for DSM-5 CBT Cognitive-behavioral therapy CE Cost-effectiveness CI Confidence interval CPT Cognitive processing therapy CRP C-reactive protein CSSRS Columbia Suicide Severity Rating Scale DEA US Drug Enforcement Agency DUDIT Drug Use Disorders Identification Test EMDR Eye Movement Desensitization and Reprocessing evLY Equal value life year FDA U.S. Food and Drug Administration HIDI Health Improvement Distribution Index I Insufficient ID Identification ITT Intention to treat LTFUQ Long-term follow-up questionnaire LSNAP Lykos-specific non-assisted psychotherapy M Markov MD Mean difference MDD Major depressive disorder MDMA 3,4-methylenedioxymethamphetamine MDMA-AP MDMA-assisted psychotherapy Mg Milligram Mod Moderate n Number N Total Number NA or N/A Not applicable NCT National Clinical Trial NH Non-Hispanic NR Not reported OUD Opioid use disorder PC Placebo-controlled PTGI Posttraumatic Growth Inventory PTSD Post-traumatic stress disorder QALY Quality adjusted life year QoL Quality of life RR Relative risk